3 completed, 2 active not recruiting, 1 recruiting. 4 Phase 1, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Primary Mediastinal Lymphoma: new trials by email Literature Review of Primary Mediastinal Lymphoma trials Research Report on Primary Mediastinal Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine - Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma | Phase 4 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 300 | 2022-05-25 | 2022-08-26 |
| Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate - Primary Mediastinal Lymphoma | Phase 3 | Active not recruiting | National Research Center for Hematology, Russia | 60 | 2022-04-01 | 2026-10-08 |
| CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML CD19-CAR_Lenti T cell - Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Bambino Gesù Hospital and Research Institute | 32 | 2021-03-04 | 2025-12-02 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors Tazemetostat and [14C] Tazemetostat - Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma | Phase 1 | Completed | Epizyme, Inc. | 3 | 2018-06-20 | 2024-03-22 |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells - Multiple Myeloma, Non-Hodgkin Lymphoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 39 | 2017-10-18 | 2022-11-04 |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients Tazemetostat, Fluconazole, Omeprazole - Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma | Phase 1 | Completed | Epizyme, Inc. | 32 | 2017-03-27 | 2023-06-26 |
Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Follicular (2) · Burkitt Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, B-Cell (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma, Non-Hodgkin (4) · Hematologic Diseases (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1)
Cyclophosphamide (2) · Doxorubicin (2) · Vincristine (2) · tazemetostat (2) · Carmustine (1) · Cytarabine (1) · Dexamethasone (1) · Etoposide (1) · Filgrastim (1) · Fluconazole (1) · Idarubicin (1) · Ifosfamide (1) · Injections (1) · Lomustine (1) · Melphalan (1)
Epizyme, Inc. (2) · Bambino Gesù Hospital and Research Institute (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Masonic Cancer Center, University of Minnesota (1) · National Research Center for Hematology, Russia (1)
Russia (2) · United States (2) · Italy (1) · United Kingdom (1)
Elena Parovichnikova, MD,PhD (1) · Veronika Bachanova, MD, PhD (1)
2016 (1)